477246-93-8

Upstream product

• 288629-12-9 2-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)ethyl aldehyde 
• 53263-18-6 allyl 2,3,4,6-tetra-O-acetyl-α-D-galactopyranoside 
• 100-39-0 benzyl bromide 
• 25878-60-8 D-galactose pentaacetate 
• 82659-55-0 3-(2',3',4',6'-tetra-O-benzyl-α-D-galactopyranosyl)prop-1-ene 

Downstream Products

• 477246-95-0 2-(2',3',4',6'-tetra-O-benzyl-α-D-galactopyranosyl)-1-iodoethane 
• 477247-00-0 (3S,5S,6R)-3-(2'-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)ethyl)-4-(tert-butoxycarbonyl)-5,6-diphenyl-2,3,5,6-tetrahydro-4H-1,4-oxazin-2-one 
• 288629-12-9 2-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl)ethyl aldehyde 

Relevant academic research and scientific papers

Synthesis of C-linked glycopyranosyl serines via a chiral glycine enolate equivalent.

[formula: see text] The stereoselective preparation of C-linked D-gluco- and D-galactopyranosyl L-serines in their alpha and beta forms is herein reported. The syntheses require the conversion of the allyl C-glycopyranosides into their iodoethyl derivativ

Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases

The invention is directed to novel compounds of formulae (I), (II) and (III): wherein X is O or NH; R3 is OH or a monosaccharide and R4 is hydrogen, or R3 is hydrogen and R4 is OH or a monosaccharide; R5 is hydrogen or a monosaccharide; and pharmaceutically acceptable salts or esters thereof. The invention is also directed to the use of the compounds both directly and as immune adjuvants for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the intermediates which can be used to make these novel compounds.